| Person Name | Explanation |
|---|---|
| Jeff Polak | * DAVID POLAK (DIRECTOR), JANET POLAK (DIRECTOR) AND JEFF POLAK PRESIDENT/DIRECTOR/EXECUTIVE DIRECTOR), OF DAVID & JANET POLAK FOUNDATION (THE "FOUNDATION"), ARE PRINCIPALS AT THE INVESTMENT MANAGEMENT FIRM POLAK INVESTORS, LLC, A DISQUALIFIED PERSON WHICH PROVIDES INVESTMENT MANAGEMENT SERVICES TO THE FOUNDATION. IN THE TAXABLE YEAR ENDING DECEMBER 31, 2022, THE FOUNDATION PAID $394,893 FOR INVESTMENT MANAGEMENT SERVICES RENDERED BY SUCH DISQUALIFIED PERSON, AS REPORTED IN PART I, LINE 16C. THE REASONABLENESS OF THE PROFESSIONAL FEES WAS ESTABLISHED BY AN OUTSIDE COMPENSATION COMMITTEE, WHICH REVIEWED THE RATES CHARGED BY COMPARABLE INVESTMENT MANAGEMENT FIRMS. |
| Description of Property | Date Acquired | Cost or Other Basis | Prior Years' Depreciation | Computation Method | Rate / Life (# of years) |
Current Year's Depreciation Expense | Net Investment Income | Adjusted Net Income | Cost of Goods Sold Not Included |
|---|
| Grantee's Name | Grantee's Address | Grant Date | Grant Amount | Grant Purpose | Amount Expended By Grantee | Any Diversion By Grantee? | Dates of Reports By Grantee | Date of Verification | Results of Verification |
|---|---|---|---|---|---|---|---|---|---|
|
NEUROVISION IMAGING INC |
1395 GARDEN HIGHWAY SUITE 250 SACRAMENTO,CA95833 |
2014-12-17 | 250,000 | PRI INVEST-SEE GEN EXPLAN FOR PURPOSE & ADDTL DETAILS RE AMT, AMT EXPENDED, & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. | ||
|
BRUIN BIOMETRICS LLC |
10960 WILSHIRE BLVD SUITE 950 LOS ANGELES,CA90024 |
2015-05-13 | 250,000 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. | ||
|
BIOP MEDICAL LTD |
10 Ohaliav St RAMAT GAN 5252263 IS |
2017-04-21 | 250,000 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. | ||
|
ONLINE DISRUPTIVE TECHNOLOGIES INC |
MATAM ADV TECH PK BLD 23 POBX 15050 HAIFA 3190501 IS |
2017-04-21 | 250,000 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. | ||
|
ORGENESIS LTD |
ARAD STREET 9 TEL AVIV IS |
2017-04-21 | 305,498 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. | ||
|
BRYN PHARMA LLC FKA EPI-NOW LLC |
518 NORTH HILLCREST ROAD BEVERLY HILLS,CA90210 |
2018-07-13 | 250,000 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. | ||
|
CYWAT TECHNOLOGIES LTD |
168 JABOTINSKY ST BNEI BRAK IS |
2018-11-26 | 250,000 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. | ||
|
BIO-ACTIVES SYNERYGIO LTD FKA YB MO CHO |
HITECH VIL 4/9 GIVAT RAM POB 39231 JERUSALEM 9129102 IS |
2018-04-20 | 250,000 | PRI LOAN-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. | ||
|
BIO-ACTIVES SYNERYGIO LTD FKA YB MO CHO |
HITECH VIL 4/9 GIVAT RAM POB 39231 JERUSALEM 9129102 IS |
2018-07-19 | 250,000 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. | ||
|
MAXQ AI LTD |
96 YIGAL ALON STREET ENTRANCE A TEL AVIV 6789140 IS |
2019-03-19 | 250,000 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. | |||
|
EXTHERA MEDICAL CORPORATION |
757 ARNOLD DRIVE SUITE B MARTINEZ,CA94553 |
2019-12-19 | 250,000 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. | ||
|
YONALINK LTD |
HADASSAH EIN KEREM HOSP POB 12000 JERUSALEM 9112001 IS |
2019-11-12 | 250,000 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. | ||
|
AMICROBE INC |
3142 TIGER RUN COURT 103 CARLSBAD,CA92010 |
2019-10-31 | 250,000 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORTS FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. | ||
|
OCTHEALTH LLC |
1395 GARDEN HIGHWAY SUITE 250 SACRAMENTO,CA95833 |
2021-06-08 | 250,000 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORT FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORT WAS MADE. | ||
|
BIO-ACTIVES SYNERGIO LTD |
HI-TECH VILLAGE UNIT 4/9 POB39231 GIVAT RAM 9129102 IS |
2021-10-12 | 100,000 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORT FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORT WAS MADE. | ||
|
CYWAT TECHNOLOGIES LTD |
168 JABOTINSKY ST BNEI BRAK IS |
2021-06-15 | 100,000 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORT FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORTS WERE MADE. | ||
|
NEUROVISION IMAGING INC |
1395 Garden Highway Suite 250 sacramento,CA95833 |
2022-06-17 | 250,000 | PRI LOAN-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORT FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORT WAS MADE. | ||
|
YAMO PHARMACEUTICALS LLC |
400 Madison Ave Ste 11A NEW YORK,NY10017 |
2022-07-13 | 250,000 | PRI INVEST-SEE GENERAL EXPLANATION FOR PURPOSE & ADDTL DETAILS RE AMT EXPENDED & LACK OF DIVERSION | NO | See General Explanation for Report Dates | THE GRANTOR HAS NO REASON TO DOUBT THE ACCURACY OR RELIABILITY OF THE REPORT FROM THE GRANTEE; THEREFORE, NO INDEPENDENT VERIFICATION OF THE REPORT WAS MADE. |
| Identifier | Return Reference | Explanation |
|---|---|---|
| FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | PRI RECIPIENT: NEUROVISION IMAGING, INC. DATES AND AMOUNTS OF PRI: 12/17/2014 $250,000 5/17/2018 $37,502 PURPOSE OF PRI: RESEARCH AND DEVELOPMENT OF DIAGNOSTIC TOOLS FOR EARLY-STAGE DETECTION OF ALZHEIMER'S DISEASE AND OTHER DEGENERATIVE NEUROLOGICAL DISORDERS. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED FULL AND COMPLETE FINANCIAL REPORTS OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 3/25/2015 FOR FYE 12/31/2014 DATE OF REPORT: 5/18/2016 FOR FYE 12/31/2015 DATE OF REPORT: 6/7/2017 FOR FYE 12/31/2016 DATE OF REPORT: 5/11/2018 FOR FYE 12/31/2017 DATE OF REPORT: 11/1/2019 FOR FYE 12/31/2018 DATE OF REPORT: 6/2/2020 FOR FYE 12/31/2019 DATE OF REPORT: 6/28/2021 FOR FYE 12/31/2020 DATE OF REPORT: 8/25/2023 FOR FYE 12/31/2021 DATE OF REPORT: 8/25/2023 FOR FYE 12/31/2022 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | PRI RECIPIENT: BRUIN BIOMETRICS, LLC DATE AND AMOUNT OF PRI: 5/13/2015 $250,000 PURPOSE OF PRI: TO PROMOTE THE HEALTH AND REDUCE THE SUFFERING OF THOSE AFFECTED BY EARLY-STAGE PRESSURE ULCERS DURING THEIR HOSPITAL STAYS AND TO ADVANCE SCIENTIFIC UNDERSTANDING THROUGH RESEARCH IN THE PUBLIC INTEREST. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORTS OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 5/24/2016 FOR FYE 12/31/2015 DATE OF REPORT: 6/29/2017 FOR FYE 12/31/2016 DATE OF REPORT: 5/15/2018 FOR FYE 12/31/2017 DATE OF REPORT: 6/14/2019 FOR FYE 12/31/2018 DATE OF REPORT: 4/22/2020 FOR FYE 12/31/2019 DATE OF REPORT: 8/25/2022 FOR FYE 12/31/2020 DATE OF REPORT: 8/11/2022 FOR FYE 12/31/2021 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | PRI RECIPIENT: BIOP MEDICAL LTD DATES AND AMOUNTS OF PRI: 4/21/2017 $250,000 PURPOSE OF PRI: TO PROMOTE THE HEALTH AND REDUCE THE SUFFERING OF THOSE AFFECTED BY DISEASE AND TO ADVANCE SCIENTIFIC UNDERSTANDING THROUGH RESEARCH IN THE PUBLIC INTEREST. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORT OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 6/4/2018 FOR FYE 12/31/2017 DATE OF REPORT: 2/12/2019 FOR FYE 12/31/2018 DATE OF REPORT: 11/13/2021 FOR FYE 12/31/2019 DATE OF REPORT: 11/13/2021 FOR FYE 12/31/2020 Although the foundation has made multiple attempts to obtain formal reports for 2021 and 2022, it has been unable to do so. However, BIOP has informally indicated that it has neither funds available nor working staff, and that its activities have been reduced to the bare minimum from the onset of the pandemic and have not since recovered. Per Section 53.4945-5(e)(2) of the Treasury Regulations, the failure of PRI Recipient to submit an annual report will not result in a taxable expenditure for the Foundation because the Foundation (i) made the grant in accordance with paragraph (b) of said section of the Regulations, (ii) has complied with the reporting requirements contained in paragraph (d) of said section of the Regulations, (iii) made a reasonable effort to obtain the required report, and (iv) will withhold all future payments on any grant to this grantee until such report is furnished. THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | PRI RECIPIENT: ONLINE DISRUPTIVE TECHNOLOGIES, INC. DATE AND AMOUNT OF PRI: 4/21/2017 $250,000 PURPOSE OF PRI: TO PROMOTE THE HEALTH AND REDUCE THE SUFFERING OF THOSE AFFECTED BY CANCER AND TO ADVANCE SCIENTIFIC UNDERSTANDING THROUGH RESEARCH IN THE PUBLIC INTEREST. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORT OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 6/6/2018 FOR FYE 12/31/2017 DATE OF REPORT: 2/12/2019 FOR FYE 12/31/2018 DATE OF REPORT: 6/1/2020 FOR FYE 12/31/2019 DATE OF REPORT: 8/18/2021 FOR FYE 12/31/2020 DATE OF REPORT: 3/20/2023 FOR FYE 12/31/2021 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | PRI RECIPIENT: BRYN PHARMA LLC F/K/A EPI-NOW LLC DATE AND AMOUNT OF PRI: 7/13/2018 $250,000 PURPOSE OF PRI: TO PROMOTE THE HEALTH OF THOSE WHO REQUIRE EPINEPHRINE AND TO ADVANCE SCIENTIFIC UNDERSTANDING THROUGH RESEARCH IN THE PUBLIC INTEREST. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORT OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 8/23/2019 FOR FYE 12/31/2018 DATE OF REPORT: 10/24/2020 FOR FYE 12/31/2019 DATE OF REPORT: 8/2/2021 FOR FYE 12/21/2020 DATE OF REPORT: 5/16/2023 FOR FYE 12/21/2021 DATE OF REPORT: 4/25/2023 FOR FYE 12/21/2022 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. APPRECIATION OF PROPERTY. |
| FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | PRI RECIPIENT: ORGENESIS LTD. DATE AND AMOUNT OF PRI: 4/21/2017 $305,498 PURPOSE OF PRI: TO PROMOTE THE HEALTH AND REDUCE THE SUFFERING OF THOSE AFFECTED BY DIABETES BY WAY OF RESEARCHING AND BRINGING TO CLINICAL TRIAL THE COMPANY TECHNOLOGY SOLUTION. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED FULL AND COMPLETE FINANCIAL REPORTS OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 9/9/2018 FOR FYE 12/31/2017 DATE OF REPORT: 10/20/2020 FOR FYE 12/31/2018 DATE OF REPORT: 10/20/2020 FOR FYE 12/31/2019 DATE OF REPORT: 5/20/2021 FOR FYE 12/31/2020 DATE OF REPORT: 5/14/2023 FOR FYE 12/31/2021 DATE OF REPORT: 5/14/2023 FOR FYE 12/31/2022 THE FOUNDATION EXERCISED AN OPTION TO EXCHANGE ITS INTEREST IN THE INVESTEE FOR THE STOCK IN THE PARENT COMPANY OF THE INVESTED. THIS WAS DONE TO PRESERVE THE PRI AND NOT TO GENERATE INCOME OR FOR THE APPRECIATION OF PROPERTY. THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | PRI RECIPIENT: CYWAT TECHNOLOGIES LTD DATES AND AMOUNTS OF PRI: 11/26/2018 $250,000 3/3/2021 $7,101 PURPOSE OF PRI: TO PROMOTE THE HEALTH OF PEOPLE WHO ARE AFFECTED BY POLLUTED DRINKING WATER BY FUNDING THE DEVELOPMENT OF A WATER MONITORING SYSTEM THAT IS DISTRIBUTED THROUGHOUT THE ENTIRE WATER GRID AND WHICH CAN IMMEDIATELY DETECT POTENTIAL DANGERS. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORT OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 6/18/2019 FOR FYE 12/31/2018 DATE OF REPORT: 1/13/2020 FOR FYE 12/31/2019 DATE OF REPORT: 1/20/2022 FOR FYE 12/31/2020 DATE OF REPORT: 1/16/2022 FOR FYE 12/31/2021 DATE OF REPORT: 6/13/2023 FOR FYE 12/31/2022 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | PRI RECIPIENT: BIO-ACTIVES SYNERGIO LTD. F/K/A Y&B MOTHERS CHOICE LTD. DATE AND AMOUNT OF PRI: 4/20/2018 $250,000 PURPOSE OF PRI: TO PROMOTE HEALTH BY FUNDING RESEARCH INTO DEVELOPING NON HAZARDOUS, NATURAL PRODUCTS THAT DO NOT ENDANGER HUMAN HEALTH. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORT OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 10/29/2020 FOR FYE 12/31/2018 DATE OF REPORT: 10/29/2020 FOR FYE 12/31/2019 DATE OF REPORT: 11/13/2022 FOR FYE 12/31/2020 DATE OF REPORT: 9/18/2023 FOR FYE 12/31/2021 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | PRI RECIPIENT: BIO-ACTIVES SYNERGIO LTD. F/K/A Y&B MOTHERS CHOICE LTD. DATE AND AMOUNT OF PRI: 7/19/2018 $250,000 PURPOSE OF PRI: TO PROMOTE HEALTH BY FUNDING RESEARCH INTO DEVELOPING NON HAZARDOUS, NATURAL PRODUCTS THAT DO NOT ENDANGER HUMAN HEALTH. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORT OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 10/29/2020 FOR FYE 12/31/2018 DATE OF REPORT: 10/29/2020 FOR FYE 12/31/2019 DATE OF REPORT: 11/13/2022 FOR FYE 12/31/2020 DATE OF REPORT: 9/18/2023 FOR FYE 12/31/2021 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | FORM 990-PF, PART VI-B, LINE 5D - EXPENDITURE RESPONSIBILITY | PRI RECIPIENT: MAXQ AI, LTD DATE OF PRI: 3/19/2019 $250,000 PURPOSE OF PRI: TO PROMOTE THE DEVELOPMENT OF A PRODUCT THAT WILL SUBSTANTIALLY BENEFIT THE PUBLIC BY INCORPORATING SOPHISTICATED ARTIFICIAL INTELLIGENCE INTO DIAGNOSTIC RADIOLOGY. REPORTS OF AMOUNTS EXPENDED: RECIPIENT HAS SUBMITTED A FULL AND COMPLETE FINANCIAL REPORT OF THE TYPE ORDINARILY REQUIRED BY COMMERCIAL INVESTORS UNDER SIMILAR CIRCUMSTANCES AND A STATEMENT THAT IT HAS COMPLIED WITH THE TERMS OF THE INVESTMENT FOR ITS FISCAL YEARS INDICATED BELOW: DATE OF REPORT: 10/13/2020 FOR FYE 12/31/2019 DATE OF REPORT: 7/20/2021 FOR FYE 12/31/2020 DATE OF REPORT: 3/24/2023 FOR FYE 12/31/2021 DATE OF REPORT: 7/7/2023 FOR FYE 12/31/2022 THIS INVESTMENT REMAINED ON THE FOUNDATION'S BOOKS AS OF 12/31/2022. DIVERSIONS: TO THE KNOWLEDGE OF THE GRANTOR, NO FUNDS HAVE BEEN DIVERTED TO ANY ACTIVITY OTHER THAN THE ACTIVITY FOR WHICH THE INVESTMENT WAS ORIGINALLY MADE. |
| Name of Bond | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| EDISON INTL BOND PERPETUAL - 5 | 1,000,149 | 818,390 |
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| AGNICO EAGLE MINES LTD | 735,250 | 816,503 |
| AMERICAN AXLE & MFG HOLDINGS I | 263,446 | 204,102 |
| ARCH COAL, INC | 84,323 | 142,790 |
| ARDAGH METAL PACKAGING SA | 76,117 | 48,100 |
| B2 GOLD CORP COM NPV | 150,587 | 150,654 |
| BARRICK GOLD CORPORATION | 757,500 | 429,500 |
| BAYER A G SPONSORED ADR | 198,370 | 102,880 |
| BERRY PLASTICS GROUP INC | 274,208 | 362,580 |
| BLOOM ENERGY CORP | 19,368 | 19,120 |
| BP PLC SPONSORED ADR | 102,249 | 104,790 |
| CAMECO CORPORATION | 19,784 | 22,670 |
| CENTERRA GOLD INC | 88,332 | 51,800 |
| CENTURY ALUMINUM COMPANY | 134,168 | 81,800 |
| CHENIERE ENERGY INC | 262,699 | 524,860 |
| CITIGROUP INC | 248,049 | 226,150 |
| CLIFFS NATURAL RESOURCES INC. | 94,101 | 96,660 |
| COMPASS MINERALS INTERNATIONAL | 82,086 | 82,000 |
| COMSTOCK RES INC | 139,670 | 287,910 |
| CONSOL ENERGY, INC | 177,409 | 390,000 |
| CONSTELLIUM NV | 136,767 | 70,980 |
| COPPER MOUNTAIN MINI NG CORP | 66,822 | 151,200 |
| COTERRA ENERGY INC | 425,563 | 590,024 |
| CVS CAREMARK CORP | 466,000 | 931,900 |
| DANA HOLDING CP | 137,340 | 121,040 |
| ELDORADO GOLD CORP COM NPV | 308,509 | 234,080 |
| ENDEAVOUR MINING CORP | 206,264 | 213,907 |
| FIDELITY CONSERV INC BD FD | 8,731 | 8,694 |
| FIRST MAJESTIC SILVER CORP | 109,720 | 83,400 |
| FIRST QUANTUM MINERALS LTD | 17,953 | 41,720 |
| FLUTTER ENTERTAINMENT ORD SHS | 90,356 | 94,325 |
| GENERAL MOTORS | 361,740 | 336,400 |
| GOLD FIELDS LTD ADS | 140,581 | 269,100 |
| GRAFTECH INTERNATIONAL LTD | 391,515 | 166,600 |
| GRAPHIC PACKAGING CORP COM STK | 41,828 | 66,750 |
| HALLIBURTON COMPANY | 226,736 | 236,100 |
| HESS CORP | 190,621 | 283,640 |
| HOLCIM LTD SPON ADS | 57,245 | 102,900 |
| HOLCIM N | 491,587 | 517,510 |
| HUDBAY MINERALS INC | 186,121 | 152,100 |
| IVANHOE MINES LTD | 60,260 | 237,000 |
| JAPAN SMALLER CAPITALIZATION F | 403,984 | 329,184 |
| JET2 PLC | 78,926 | 115,286 |
| JOHNSON & JOHNSON | 231,728 | 441,625 |
| KAZATOMPROM JSC NAC GDR | 147,503 | 281,400 |
| MARKET VECTORS VIETNAM ETF | 40,705 | 23,680 |
| MERCK & CO INC | 226,844 | 554,750 |
| MICRON TECHNOLOGY | 300,822 | 549,780 |
| NEWCREST MINING LTD | 109,012 | 134,830 |
| NEWMONT GOLDCORP CORPORATION | 574,088 | 748,403 |
| NEXGEN ENERGY LTD | 115,963 | 155,050 |
| NOVAGOLD RESOURCES | 108,485 | 119,600 |
| NUVEEN MLT STR I&G | 9,760 | 7,280 |
| OCEANAGOLD CORPORATION COM | 142,250 | 114,000 |
| ORGANON & CO | 18,170 | 22,344 |
| PEABODY ENERGY CORP | 111,551 | 132,100 |
| PFIZER INC | 294,452 | 614,880 |
| PHILIP MORRIS INTL | 8,916 | 10,121 |
| SHELL ADR EACH REPRESENTING 2 | 202,042 | 227,800 |
| TEVA PHARMACEUTICAL INDUSTRIES | 36,513 | 9,120 |
| THE MOSAIC CO | 306,123 | 350,960 |
| TOREX GOLD RESOURCES | 181,332 | 172,500 |
| TPG RE FINANCE TRUST INC | 2,013 | 679 |
| TRUIST FINANCIAL CORPORATION | 30,848 | 43,030 |
| UNITED STATES STEEL CORP | 48,470 | 50,100 |
| VALARIS LTD WTS EXP 04/29/2028 | 220,170 | 1,142 |
| VALARIS PLC COM CL A | 161,969 | |
| VIATRIS ORD SHS | 90,189 | 72,134 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| AIR U.S. LIFE FUND III, LP | 2,091,530 | 2,156,858 | |
| AIR US LIFE FUND IV, LP | 1,996,407 | 2,149,384 | |
| ALPHA WAVE (F/K/A FALCON EDGE) | 551,806 | 1,332,337 | |
| ALTAIR - PACIFIC COAST CPTL PT | 467,684 | 365,083 | |
| ALTAIR DIRECT LENDING FUND, LL | 166,151 | 149,222 | |
| ALTAIR EUROPEAN R E OPPORTUNIT | 659,098 | 226,593 | |
| ALTAIR SENIOR HOUSING FUND (AE | 49,830 | 451,866 | |
| ANAGENESIS CAPITAL PARTNERS SB | 1,247,114 | 2,139,296 | |
| ASM CONNAUGHT HOUSE FUND III L | 1,000,000 | 1,278,344 | |
| AVANTE CAPITAL PARTNERS SBIC I | 229,509 | 234,765 | |
| BROAD ST REAL ESTATE CREDIT PT | 139,481 | ||
| BW GAS & CONVENIENCE ONSHORE F | 1 | 3,040,428 | |
| DORCHESTER CAPITAL SECONDARIES | 810,630 | 1,063,452 | |
| ENLIGHTENMENT CAP SOLUTION III | 1,385,602 | 3,163,935 | |
| ENLIGHTENMENT CAP SOLUTION IV | 440,192 | 449,928 | |
| FIRST EAGLE CLO EQUITY FUND I, | 280,004 | 176,406 | |
| FOURTHSTONE SMALL-CAP FINANCIA | 353,864 | 414,152 | |
| GOLDMAN SACHS VINTAGE FUND V L | 302,066 | 82,615 | |
| GRANITE CREEK FLEXCAP II, L.P | 1,030,020 | 1,113,908 | |
| GS DISTRESSED OPPORTUNITIES FU | 133,187 | 135,718 | |
| GSO CAPITAL SOLUTIONS FD II 1 | 6,008 | 2,678 | |
| GSO CAPITAL SOLUTIONS FD II 2 | 77,804 | 26,952 | |
| GSO CAPITAL SOLUTIONS FD II LP | 266,762 | 118,905 | |
| GSO ENERGY SELECT OPP FD AIV-2 | 74,433 | 86,351 | |
| GSO ENERGY SELECT OPP FD AIV-3 | 57,108 | 53,389 | |
| GSO ENERGY SELECT OPP FD AIV-5 | 1,287 | 1,203 | |
| GSO ENERGY SELECT OPP FUND | 14,932 | 13,400 | |
| LATITUDE MGMT RE CAP III | 40,000 | 22,479 | |
| LATITUDE MGMT RE CAP IV | 2,000,000 | 2,022,277 | |
| PCCP EQUITY VII, LP | 1,818,674 | 2,812,522 | |
| PCCP EQUITY VIII, LP | 685,393 | 933,217 | |
| QS CAPITAL STRATEGIES II, L.P | 686,664 | 713,701 | |
| SILVERVIEW CREDIT OPP FUND LP | 55,573 | 90,230 | |
| SILVERVIEW CREDIT OPP OFFSHORE | 1,300,213 | 1,300,213 | |
| THE EDGBASTON ASIAN EQUITY TRU | 1,421,237 | 1,226,351 | |
| BERNIE L MADOFF - CLAIM RECEIV | 346,222 | 346,222 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| Document Review/Drafting | 12,453 | 12,453 | ||
| General Consultations | 5,470 | 5,470 |
| Description | Beginning of Year - Book Value | End of Year - Book Value | End of Year - Fair Market Value |
|---|---|---|---|
| PRI - AMICROBE, INC | 250,000 | 250,000 | |
| PRI - BARAK BALLET | 200,000 | 200,000 | |
| PRI - BIOP MEDICAL | 250,000 | 250,000 | |
| PRI - BRUIN_BIOMETRICS | 250,000 | 250,000 | |
| PRI - BRYN PHARMA LLC F/K/A EP | 250,000 | 250,000 | |
| PRI - CYWAT TECH | 507,100 | 507,101 | |
| PRI - EXTHERA MEDICAL CORP | 250,000 | 250,000 | |
| PRI - MAXQ AI, LTD | 250,000 | 250,000 | |
| PRI - MOTHERS CHOICE | 250,000 | 250,000 | |
| PRI - MOTHERS CHOICE (2) | 250,000 | 250,000 | |
| PRI - NEUROVISION IMAGING, INC | 250,000 | 250,000 | |
| PRI - OCTHEALTH LLC - 15,000 U | 250,000 | 250,000 | |
| PRI - ONLINE DISRUPTIVE | 250,000 | 250,000 | |
| PRI - ORGENESIS - 32,052 SHARE | 294,398 | 183,658 | |
| PRI - ORGENESIS WTS - 32,052 U | 11,100 | ||
| PRI - SER A1 PFD (82,175 UNITS | 250,000 | 250,000 | |
| PRI - SER A2 PFD (15,408 UNITS | 37,502 | 37,502 | |
| PRI - SYNERGIO BIO ACTIVES LTD | 100,000 | 100,000 | |
| PRI - YAMO PHARMACEUTICALS LLC | 250,000 | 250,000 | |
| PRI - YONALINK LTD | 250,000 | 250,000 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| Administrative Fees | 93,698 | 93,698 | ||
| Bank Charges | 1,091 | 1,091 | ||
| Cell Phone Expense | 822 | 822 | ||
| Insurance Premiums | 1,129 | 1,129 | ||
| K-1 Exp AIR U.S. LIFE FUND III | 131,124 | 131,124 | ||
| K-1 Exp AIR US LIFE FUND IV, L | 84,930 | 84,930 | ||
| K-1 Exp ALPHA WAVE (F/K/A FALC | 7,931 | 7,931 | ||
| K-1 Exp ALTAIR - PACIFIC COAST | 12,873 | 12,871 | ||
| K-1 Exp ALTAIR DIRECT LENDING | 1,057 | 1,047 | ||
| K-1 Exp ALTAIR SENIOR HOUSING | 3,259 | 3,209 | ||
| K-1 Exp ANAGENESIS CAPITAL PAR | 152,411 | 151,900 | ||
| K-1 Exp AVANTE CAPITAL PARTNER | 56,039 | 50,467 | ||
| K-1 Exp BW GAS & CONVENIENCE O | 434 | 172 | ||
| K-1 Exp ENLIGHTENMENT CAPITAL | 50,232 | 50,145 | ||
| K-1 Exp ENLIGHTENMENT CAPITAL | 37,316 | 37,216 | ||
| K-1 Exp FIRST EAGLE CLO EQUITY | 8,607 | 8,607 | ||
| K-1 Exp FOURTHSTONE SMALL-CAP | 6,117 | 6,117 | ||
| K-1 Exp GRANITE CREEK FLEXCAP | 8,190 | 8,070 | ||
| K-1 Exp GSO CAPITAL SOLUTIONS | 2,540 | -14 | ||
| K-1 Exp GSO CAPITAL SOLUTIONS | 2,050 | 2,050 | ||
| K-1 Exp GSO ENERGY SELECT OPPO | 17,700 | 1,643 | ||
| K-1 Exp GSO ENERGY SELECT OPPO | 955 | 854 | ||
| K-1 Exp GSO ENERGY SELECT OPPO | 122 | 122 | ||
| K-1 Exp GSO ENERGY SELECT OPPO | 646 | 646 | ||
| K-1 Exp PCCP EQUITY VII, LP | 34,364 | 34,283 | ||
| K-1 Exp PCCP EQUITY VIII, LP | 5,671 | 5,663 | ||
| K-1 Exp QS CAPITAL STRATEGIES | 71,205 | 71,175 | ||
| K-1 Exp SILVERVIEW CREDIT OPPO | 2,147 | 2,147 | ||
| K-1 Exp THE EDGBASTON ASIAN EQ | 5,201 | 4,920 | ||
| PARKING FEES | 3,180 | 3,180 | ||
| OFFICE SUPPLIES | 5,708 | 5,708 | ||
| Postage/Delivery Service | 68 | 68 | ||
| Registered Agent Fee | 125 | 125 | ||
| State or Local Filing Fees | 250 | 250 | ||
| Website Hosting/Support | 576 | 576 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| K-1 Inc/Loss AIR U.S. LIFE FUND III, LP | 51 | 51 | |
| K-1 Inc/Loss AIR US LIFE FUND IV, LP | 71 | 71 | |
| K-1 Inc/Loss ALTAIR - PACIFIC COAST CPTL PTNRS EQ | -9,724 | -6,856 | |
| K-1 Inc/Loss ALTAIR DIRECT LENDING FUND, LLC | 461 | 461 | |
| K-1 Inc/Loss ALTAIR SENIOR HOUSING FUND (AEW), LL | -24,794 | -549 | |
| K-1 Inc/Loss ANAGENESIS CAPITAL PARTNERS SBIC FUN | 227,787 | 281,248 | |
| K-1 Inc/Loss AVANTE CAPITAL PARTNERS SBIC III, LP | 47,540 | 44,641 | |
| K-1 Inc/Loss BW GAS & CONVENIENCE ONSHORE FUND, L | -248,550 | ||
| K-1 Inc/Loss ENLIGHTENMENT CAPITAL SOLUTIONS FUND | 157,552 | 130,810 | |
| K-1 Inc/Loss ENLIGHTENMENT CAPITAL SOLUTIONS FUND | 18,743 | 10,286 | |
| K-1 Inc/Loss FIRST EAGLE CLO EQUITY FUND I, LP | 42,210 | 42,210 | |
| K-1 Inc/Loss FOURTHSTONE SMALL-CAP FINANCIALS FD | 6,573 | 5,939 | |
| K-1 Inc/Loss GRANITE CREEK FLEXCAP II, L.P | 60,368 | 60,368 | |
| K-1 Inc/Loss GSO CAPITAL SOLUTIONS FUND II AIV-1 | -19 | -19 | |
| K-1 Inc/Loss GSO CAPITAL SOLUTIONS FUND II AIV-2 | -10,435 | 8 | |
| K-1 Inc/Loss GSO CAPITAL SOLUTIONS FUND II LP | 26,906 | 26,857 | |
| K-1 Inc/Loss GSO ENERGY SELECT OPPORTUNITIES FUND | 26,282 | 81 | |
| K-1 Inc/Loss GSO ENERGY SELECT OPPORTUNITIES FUND | 9 | 8 | |
| K-1 Inc/Loss PCCP EQUITY VII, LP | 132,484 | 38,657 | |
| K-1 Inc/Loss PCCP EQUITY VIII, LP | -11,146 | 1,706 | |
| K-1 Inc/Loss QS CAPITAL STRATEGIES II, L.P | 81,245 | 111,556 | |
| K-1 Inc/Loss SILVERVIEW CREDIT OPPORTUNITES OFFSH | 138,430 | 138,430 | |
| K-1 Inc/Loss THE EDGBASTON ASIAN EQUITY TRUST | 67,191 | 67,191 | |
| Federal Tax Refund | 117,578 | ||
| Foreign Currency Loss | -1,254 | -1,254 | |
| State Tax Refund | 38,051 |
| Description | Amount |
|---|---|
| RETURNED GRANT | 1,000 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| PROGRAMMER SERVICES | 1,000 | 1,000 | ||
| EMPLOYEE RECRUITING SERVICES | 32,500 | 32,500 | ||
| Investment Management Services | 409,834 | 409,834 | ||
| DESIGNER SERVICES | 3,000 | 3,000 | ||
| Philanthropic Consulting Srvcs | 101,600 | 101,600 | ||
| PROJECT MANAGEMENT SERVICES | 1,000 | 1,000 | ||
| PHOTO SERVICES | 500 | 500 | ||
| VIDEO PRODUCTION | 12,136 | 12,136 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| 990-PF Estimated Tax for 2022 | 41,900 | |||
| 990-T Extension for 2021 | 70,100 | |||
| 990-T Income Tax for 2021 | 1,104 | |||
| Foreign Tax Paid | 17,659 | 17,659 | ||
| IRS MISCELLANEOUS FEE | 9 | |||
| STATE INCOME TAX 2021 | 31,100 |